ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc.

Ars Pharmaceuticals, Inc. (($SPRY)) has held its Q2 earnings call. Read on for the main highlights of the call. Ars Pharmaceuticals’ latest earning...

Ars Pharmaceuticals Charts Cost-Disciplined Path After Q2

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is facing a federal securities lawsuit over allegations that investors were misled about the timing and lik...

ARS Pharmaceuticals Lawsuit Focuses on Alleged Neffy Coverage Disclosures and SPRY Stock Drop 

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nektar Therapeutics (NKTR), Kodiak Sciences (KOD) an...

Analysts’ Top Healthcare Picks: Nektar Therapeutics (NKTR), Kodiak Sciences (KOD)

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is facing a federal securities lawsuit alleging that the company misled investors about the expected timing...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRY	$5.89	-2.32%	1.19M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRY	$5.89	-2.3%	1.19M
3
4
5
6

SPRY

Get ARS Pharmaceuticals, Inc. Data in Excel

Get ARS Pharmaceuticals, Inc. Data in Excel